JP2023530379A - 環状ｒｎａ発現のための組成物および方法 - Google Patents

環状ｒｎａ発現のための組成物および方法 Download PDF

Info

Publication number
JP2023530379A
JP2023530379A JP2022547232A JP2022547232A JP2023530379A JP 2023530379 A JP2023530379 A JP 2023530379A JP 2022547232 A JP2022547232 A JP 2022547232A JP 2022547232 A JP2022547232 A JP 2022547232A JP 2023530379 A JP2023530379 A JP 2023530379A
Authority
JP
Japan
Prior art keywords
circrna
aav
coding sequence
intron
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022547232A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530379A5 (https=
Inventor
アラビンド アソカン，
リタ メガンク，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2023530379A publication Critical patent/JP2023530379A/ja
Publication of JP2023530379A5 publication Critical patent/JP2023530379A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022547232A 2020-02-04 2021-04-01 環状ｒｎａ発現のための組成物および方法 Pending JP2023530379A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062969758P 2020-02-04 2020-02-04
US62/969,758 2020-02-04
PCT/US2021/025463 WO2021159129A2 (en) 2020-02-04 2021-04-01 Compositions and methods for circular rna expression

Publications (2)

Publication Number Publication Date
JP2023530379A true JP2023530379A (ja) 2023-07-18
JP2023530379A5 JP2023530379A5 (https=) 2024-04-08

Family

ID=77199626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022547232A Pending JP2023530379A (ja) 2020-02-04 2021-04-01 環状ｒｎａ発現のための組成物および方法

Country Status (6)

Country Link
US (1) US12600987B2 (https=)
EP (1) EP4100523A4 (https=)
JP (1) JP2023530379A (https=)
AU (1) AU2021216593A1 (https=)
CA (1) CA3168840A1 (https=)
WO (1) WO2021159129A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024003262A (es) 2021-09-17 2024-06-19 Flagship Pioneering Innovations Vi Llc Composiciones y metodos para producir poliribonucleotidos circulares.
JP2026500226A (ja) * 2022-12-07 2026-01-06 サーキヨ・アクチエボラグ ｃｉｒｃＲＮＡ発現コンストラクト
CN121241137A (zh) * 2023-05-24 2025-12-30 南京金斯瑞生物科技有限公司 用于制备环状rna的载体和方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107447033A (zh) * 2017-09-15 2017-12-08 东南大学 一种结直肠癌诊断生物标志物及其应用
WO2019094486A1 (en) * 2017-11-07 2019-05-16 The University Of North Carolina At Chapel Hill Methods and compositions for circular rna molecules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20020253A1 (it) 2002-05-08 2003-11-10 Univ Roma Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche.
FR2874384B1 (fr) 2004-08-17 2010-07-30 Genethon Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107447033A (zh) * 2017-09-15 2017-12-08 东南大学 一种结直肠癌诊断生物标志物及其应用
WO2019094486A1 (en) * 2017-11-07 2019-05-16 The University Of North Carolina At Chapel Hill Methods and compositions for circular rna molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JULIA SALZMAN ET AL.: ""Cell-Type Specific Features of Circular RNA Expression"", PLOS GENETICS, vol. 9, no. 9, JPN6025008567, 5 September 2013 (2013-09-05), pages 1003777, ISSN: 0005741234 *

Also Published As

Publication number Publication date
US20230072954A1 (en) 2023-03-09
WO2021159129A2 (en) 2021-08-12
EP4100523A2 (en) 2022-12-14
US12600987B2 (en) 2026-04-14
EP4100523A4 (en) 2024-03-06
CA3168840A1 (en) 2021-08-12
AU2021216593A1 (en) 2022-08-25
WO2021159129A3 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
JP7315284B2 (ja) 加齢関連疾患及び症状の遺伝子治療法
JP7504967B2 (ja) ＭｅＣＰ２発現カセット
JP7385282B2 (ja) 環状ｒｎａ分子のための方法及び組成物
US11999965B2 (en) Bocaparvovirus small noncoding RNA and uses thereof
US20200155624A1 (en) Compositions and methods of treating huntington's disease
TWI910162B (zh) 跨物種相容腺相關病毒組合物及其使用方法
RS63416B1 (sr) Sistem višestrukih vektora i njegove primene
KR20160033217A (ko) 변종 ａａｖ 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
US20250327094A1 (en) Modified aav constructs and uses thereof
JP2023530379A (ja) 環状ｒｎａ発現のための組成物および方法
JP2024111074A (ja) 脊髄性筋萎縮症のための併用療法
US20250195693A1 (en) Compositions Comprising Adeno-Associated Virus Chimera Capsid Proteins and Methods of Using the Same
CA3130221A1 (en) Compositions and methods for treating oculopharyngeal muscular dystrophy (opmd)
US11767541B1 (en) Adeno-associated virus complex with improved expression of RUNX3 gene and uses for preventing or treating KRAS mutated lung cancer
US20250011791A1 (en) Rnai therapy for apbd and lafora disease
US20210353775A1 (en) Method and composition for treating neuropathic pain
WO2025096498A1 (en) Compositions and methods for treating diseases or conditions associated with progerin expression
Mason SRSF1-mediated gene therapy as a therapeutic approach for C9ORF72-related amyotrophic lateral sclerosis and fronto-temporal dementia (ALS-FTD)
TW202449166A (zh) Ｄｍ－１肌強直性營養不良的靶向基因療法
WO2025102034A1 (en) Gene therapy for barth syndrome
WO2025194082A1 (en) Compositions and methods for delivering nucleic acids to podocytes
EP4709868A1 (en) Recombinant aav constructs for increased transgene expression
HK40015201B (zh) Shrna表达框、携带其的多核苷酸序列及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240327

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260331

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260424